
Jeffrey Smith
Senior Fellow
1411 K Street N.W., Suite 900 Washington, D.C. 20005
Jeff Smith is a senior fellow for the R Street Institute, where he explores tobacco control and harm reduction from the perspective of clarifying the risks associated with the use of combustible products and the potential of reduced-risk nicotine products to ameliorate disease and death related to smoking. Before joining R Street’s Healthier Communities team, Jeff was a principal scientist in the science and regulatory affairs group at Reynolds American Inc. There, he developed and implemented research procedures to evaluate reduced-risk products—including a novel technique to measure how individuals use electronic nicotine delivery systems—and explored opportunities for potential new product categories beyond nicotine. During a 20-year career in academia, Jeff served as endowed chair of health sciences at Saginaw Valley State University and held professorships at universities in Oregon and Ohio. He published widely in neuroplasticity literature, mentored countless undergraduates, held multiple leadership positions and taught a variety of courses in the behavioral and neurosciences. Jeff holds bachelor’s and master’s degrees in psychology from Georgia College and State University and a doctorate in behavioral neuroscience from Emory University. He lives in Winston-Salem, North Carolina, with his wife and three lovely cats.
Topics
Appearances (1)
2026-07-23
R Street Institute’s Jeffrey Smith Says Tobacco Harm Reduction Policy Should Focus on Science, Not PerceptionIn the latest episode of the Health Policy Podcast, Jeffrey Smith, a Senior Fellow at the R Street Institute, discusses the importance of focusing tobacco harm reduction policy on scientific evidence rather than public perception. Smith emphasizes the differences in risk between combustible tobacco products and electronic nicotine delivery systems, advocating for a marketplace that offers various reduced-risk options to help smokers transition away from traditional cigarettes. He also addresses the challenges of regulatory approaches and the need for informed decision-making among policymakers.
Notable quotes
“I think that's really slowing the process down.”
“The research is pretty clear that it can help you improve cognitive performance, especially in the frontal cortex of the brain.”
“The toxicological risk of a cigarette to the toxicological risk of an ENDS product, they're just two very different products.”
“The science just doesn't support that at all.”
“If we get it right, then there's a good chance that other countries will get it right as well.”
“The key is, how do we build products that allow adults to move away from cigarettes?”





